Pharmacokinetic/pharmacodynamic modelling and in vitro simulation of dynamic voriconazole-Candida interactions.

[1]  L. Zhong,et al.  A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro. , 2008, International journal of antimicrobial agents.

[2]  H. Derendorf,et al.  Measurement of Voriconazole Activity against Candida albicans, C. glabrata, and C. parapsilosis Isolates Using Time-Kill Methods Validated by High-Performance Liquid Chromatography , 2007, Antimicrobial Agents and Chemotherapy.

[3]  H. Derendorf,et al.  Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. , 2007, International journal of antimicrobial agents.

[4]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[5]  M. Ghannoum,et al.  Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints , 2006, Journal of Clinical Microbiology.

[6]  E. Schuck,et al.  Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Once-Daily Treatment Using Ciprofloxacin in an Extended-Release Dosage Form* , 2005, Infection.

[7]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[8]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[9]  Russell E. Lewis,et al.  Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology , 2000, Antimicrobial Agents and Chemotherapy.

[10]  J. Rex,et al.  Microdilution Susceptibility Testing of Amphotericin B, Itraconazole, and Voriconazole against Clinical Isolates of Aspergillus and FusariumSpecies , 1999, Journal of Clinical Microbiology.

[11]  M. Rinaldi,et al.  In vitro activity of voriconazole against selected fungi. , 1998, Medical mycology.

[12]  A. Espinel-Ingroff.  In Vitro Activity of the New Triazole Voriconazole (UK-109,496) against Opportunistic Filamentous and Dimorphic Fungi and Common and Emerging Yeast Pathogens , 1998, Journal of Clinical Microbiology.

[13]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[14]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.